Stock Analiz

DocGo Inc. DCGO

Medical/Nursing Services · IPO 2020 · data as of November 13, 2026

$0.21Market cap $21M
Open the interactive analysis →

DocGo Inc. (DCGO) is a healthcare company listed in the US with a market value of about $21M. In the twelve months to September 30, 2026 it had revenue of $297M and net income of -$181M, a net margin of -61.0%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (2/5); the weakest is future growth (0/5).

Key numbers: 5-year revenue growth of 28% a year, a 5-year average ROIC of -13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 193% above the current price.

About DocGo

DocGo is listed in the US and classified in medical/nursing services, IPO year 2020. Revenue went from $94M in 2020 to $322M in 2025, growth of about 27.9% a year. It was profitable in 4 of the last 6 years in our data. Its share count fell by 4% over three years (buybacks). It spends 4% of revenue on research and development.

Score: 1.0 / 5

Value1/5
Future growth0/5
Track record1/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.1
P/B0.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-147.7%
Shareholder yield52.7%
Intrinsic value vs. price+193%

Growth and quality

Revenue growth (1 yr)-47.7%
Revenue growth (5 yrs, per year)27.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)5.2%
Net margin (5-yr avg.)-7.4%
ROIC (5-yr avg.)-13.5%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$297M$322M$617M$624M$441M$319M$94M
Net income-$181M-$182M$20M$7M$35M$24M-$15M
Free cash flow-$30M$30M$67M-$72M$26M-$7M-$15M
EPS (diluted)$-1.83$-1.84$0.18$0.06$0.34$0.25$-0.25
Net margin-61.0%-56.6%3.2%1.1%7.8%7.4%-15.7%
ROIC—-89.9%6.8%3.0%6.1%6.6%-18.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $1.38, 562% above the current price; targets range from $1.00 to $2.50; the consensus rating is “Buy”; expected EPS is $-0.93 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is DocGo stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 193% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does DocGo pay a dividend?

Not currently.

Is DocGo a good stock to buy?

We do not give buy or sell advice. DocGo scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.